Responses
Poster Presentations
Scleroderma, myositis and related syndromes - clinical aspects and treatment
SAT0450 Rituximab in Systemic Sclerosis. Results of an up to Seven Years, Open Label, Multicenter Study with a Follow-up of 89 Patient-Years
Compose a Response to This Article
Other responses
No responses have been published for this article.